“…Of particular interest to the present study is the enhanced consumption of readily available psychoactive substances as one moves along the SSp, such as i) tobacco in schizotypy (Esterberg, Goulding, McClure-Tone, & Compton, 2009;Williams, Wellman, Allan, et al, 1996) and schizophrenia patients (de Leon, Diaz, Rogers, Browne, & Dinsmore, 2002), ii) cannabis in schizotypy (Barkus, Stirling, Hopkins, & Lewis, 2006;Skosnik, Spatz-Glenn, & Park, 2001;Williams, Wellman, & Rawlins, 1996) and schizophrenia (Barnes, Mutsatsa, Hutton, Watt, & Joyce, 2006), and iii) caffeine in schizotypy (Jones & Fernyhough, 2009) and schizophrenia (Gurpegui, Aguilar, Martinez-Ortega, Diaz, & de Leon, 2004). While some authors have suggested that dopamineenhancing drugs such as nicotine (Montgomery, Lingford-Hughes, Egerton, Nutt, & Grasby, 2007;Murphy et al, 2002) might be involved in the development of psychosis or some aspects of it (Abi-Dargham et al, 1998;Moore et al, 2007;Smith et al, 2009), others suggest that at-risk individuals may use nicotine as means of self medication (Adler, Hoffer, Wiser, & Freedman, 1993;Kumari & Postma, 2005;Zabala et al, 2009;Zammit et al, 2003).…”